Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTILS.L Regulatory News (TILS)

  • There is currently no data for TILS

Director/PDMR Shareholding

12 Dec 2006 18:33

ReGen Therapeutics PLC12 December 2006 Notification of Change in Interests of Directors London: On 12 December 2006 options ("Options") were granted to directors of theCompany in respect of an aggregate of 43,200,000 ordinary shares of 0.1p each inthe Company ("Ordinary Shares"). The Options, taken with existing options andwarrants over Ordinary Shares, will, if exercised, represent 5.77 per cent ofthe then enlarged issued share capital of the Company. All Options were granted with an exercise price of 1.25p per Ordinary Share (theclosing mid-market price on 12 December 2006) and may normally be exercisedbetween 31 December 2007 and 12 December 2016. The exercise of all Options issubject to first meeting performance conditions based on product launch andachieving certain revenue and profit targets over 2007, 2008 and 2009. Prior toreceiving these grants the executive Directors cancelled all previously grantedoptions (which were not subject to performance targets). No amounts were paid for the grants themselves. Percy Lomax was granted 13,000,000 Options. Following this announcement Mr Lomaxholds a total of 2,282,069 Ordinary Shares (representing 0.33 per cent of issuedshare capital) and 13,000,000 options over Ordinary Shares in the capital of theCompany. Timothy Shilton was granted 9,000,000 Options. Following this announcement MrShilton holds a total of 500,000 Ordinary Shares (representing 0.07 per cent ofissued share capital) and 9,000,000 options over Ordinary Shares in the capitalof the Company. Norman Lott was granted 8,000,000 Options. Following this announcement Mr Lottholds a total of 182,000 Ordinary Shares (representing 0.026 per cent of issuedshare capital) and 8,000,000 options over Ordinary Shares in the capital of theCompany. Martin Small was granted 8,000,000 Options. Following this announcement Mr Smallholds a total of 2,248,736 Ordinary Shares (representing 0.32 per cent of issuedshare capital) and 8,000,000 options over Ordinary Shares in the capital of theCompany. Keith Corbin was granted 2,700,000 Options. Following this announcement MrCorbin holds a total of 1,105,000 Ordinary Shares (representing 0.16 per cent ofissued share capital) and 3,300,000 options over Ordinary Shares in the capitalof the Company. Peter Garrod was granted 2,500,000 Options. Following this announcement MrGarrod holds a total of 66,750,000 Ordinary Shares (representing 9.61 per centof issued share capital) and 2,500,000 options over Ordinary Shares in thecapital of the Company. Further Information Andrew Marshall, Greycoat Communications Tel: 020 7960 6007 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
30th Mar 202112:30 pmRNSAccustem Update
30th Mar 20217:00 amRNSP2 Study in Moderate to Severe Covid-19 Patients
29th Mar 20211:02 pmRNSUpdated: Gabriele Cerrone, Bloomberg Interview
29th Mar 20217:00 amRNSChairman of Tiziana to give interview on Bloomberg
26th Feb 20217:00 amRNSTiziana Interview to Air on Bloomberg TV
16th Feb 20212:37 pmRNSTiziana at BIO CEO & Investor Digital Conference
5th Feb 20217:10 amRNSDirector/PDMR Shareholding
5th Feb 20217:00 amRNSAPPOINTMENT OF DIRECTOR
3rd Feb 20217:00 amRNSCEO exclusive interview to discuss COVID-19 Trial
2nd Feb 20214:41 pmRNSSecond Price Monitoring Extn
2nd Feb 20214:36 pmRNSPrice Monitoring Extension
2nd Feb 20219:05 amRNSSecond Price Monitoring Extn
2nd Feb 20219:00 amRNSPrice Monitoring Extension
2nd Feb 20217:00 amRNSPositive Data: Nasal Administration of Foralumab
27th Jan 20217:00 amRNSTiziana files F-3 Statement with U.S. SEC
26th Jan 20217:00 amRNSUpdated corporate presentation
20th Jan 202111:04 amRNSB. Riley Virtual Oncology Investor Conference
20th Jan 20217:00 amRNSAIM Delisting and Admission to the Main Market
13th Jan 20217:00 amRNSAppointment of Chief Medical Officer
11th Jan 20214:46 pmRNSTiziana at J.P. Morgan Healthcare Conference 2021
11th Jan 20212:48 pmRNSTiziana to Present at Biotech Showcase Digital
4th Jan 20219:05 amRNSSecond Price Monitoring Extn
4th Jan 20219:00 amRNSPrice Monitoring Extension
4th Jan 20217:00 amRNSCompletion of Foralumab Clinical Trial in Brazil
18th Dec 202011:13 amRNSPublication of Prospectus
17th Dec 20203:00 pmRNSNotification of Admission to the Main Market
10th Dec 20207:00 amRNSDirector/PDMR Shareholding
1st Dec 20207:00 amRNSTiziana Life Sciences to Host Investor Update Call
18th Nov 20202:00 pmRNSDirector/PDMR Shareholding
11th Nov 20207:00 amRNSPhase 1b/2 Clinical Trial - Crohn's Disease
9th Nov 20202:05 pmRNSSecond Price Monitoring Extn
9th Nov 20202:00 pmRNSPrice Monitoring Extension
2nd Nov 20209:05 amRNSSecond Price Monitoring Extn
2nd Nov 20209:00 amRNSPrice Monitoring Extension
2nd Nov 20207:00 amRNSInitiation of Clinical Trial for COVID-19 Patients
29th Oct 20207:00 amRNSExercise of Options, Issue of Equity, PDMR Dealing
29th Oct 20207:00 amRNSDemerger Update and Timetable Confirmation
28th Oct 20207:00 amRNSIssue of Equity on Exercise of Warrants
27th Oct 20204:00 pmRNSDemerger of StemPrintER
26th Oct 20207:00 amRNSExercise of Options, Issue of Equity, PDMR Dealing
22nd Oct 20204:36 pmRNSIssue of Equity on Exercise of Warrants
21st Oct 20207:00 amRNSExercise of Options, Issue of Equity, PDMR Dealing
20th Oct 20207:00 amRNSIssue of Equity on Exercise of Warrants
2nd Oct 202012:00 pmRNSResult of GM
30th Sep 20207:00 amRNSHalf-year Report
25th Sep 20204:40 pmRNSSecond Price Monitoring Extn
25th Sep 20204:35 pmRNSPrice Monitoring Extension
25th Sep 20207:00 amRNSInterview - Bloomberg International
21st Sep 20202:11 pmRNSPublication of Research Note
21st Sep 20207:00 amRNSIssue of Equity and Total Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.